MET and ALK as targets for the treatment of NSCLC

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Tyrosine-kinase receptors (RTKs) regulate fundamental cellular processes, and their aberrant signaling drives cancer growth.
• Activated epidermal growth factor receptor (EGFR) is a key target in non-small cell lung cancer (NSCLC).
• The oncogenic roles of hepatocyte growth factor receptor (MET) and anaplastic lymphoma kinase (ALK) are increasingly recognized in NSCLC.

Purpose of the Study:

• To review the MET and ALK pathways in the context of cancer.
• To discuss various strategies for inhibiting MET and ALK.
• To explore potential approaches for overcoming acquired resistance to kinase inhibitors targeting MET and ALK.

Main Methods:

• Literature review of scientific publications.
• Analysis of therapeutic strategies targeting MET and ALK.
• Discussion of resistance mechanisms and potential counter-strategies.

Main Results:

• MET and ALK are validated oncogenic drivers in NSCLC.
• Multiple therapeutic strategies targeting MET and ALK have been developed.
• Acquired resistance to kinase inhibitors is a significant clinical challenge.

Conclusions:

• Targeting MET and ALK offers therapeutic opportunities in NSCLC.
• Overcoming resistance is crucial for durable patient responses.
• Further research into novel inhibition strategies and resistance mechanisms is warranted.